Paige Announces Collaboration with Janssen to Deploy an AI-Based Biomarker Test

Paige AI, Inc. entered into a collaboration with Janssen Research & Development, LLC (Janssen) to evaluate the potential of a hematoxylin and eosin (H&E)-based, artificial intelligence (AI)-powered biomarker test to predict the presence of certain actionable alterations in the fibroblast growth factor receptor (FGFR) genes in patients with advanced urothelial cancer, also known as bladder cancer. This biomarker test, developed by Janssen, is a screening tool to predict the occurrence of actionable genomic alterations. The goal is to improve rates of confirmatory molecular testing and accelerate recruitment of patients into biomarker-driven clinical trials that are enrolling patients with certain tumor FGFR mutations. The technology is currently being evaluated in Janssen’s clinical trials to screen for FGFR gene alterations in adult patients with advanced urothelial cancer using the Paige Platform, a comprehensive digital pathology software platform that is inclusive of an FDA-cleared and CE-marked viewer and storage capabilities that is compatible with existing digital pathology solutions, including most scanners, monitors, and laboratory information systems (LIS).